Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Curaleaf Holdings Inc T.CURA

Alternate Symbol(s):  CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.


TSX:CURA - Post by User

Post by davgroon Aug 30, 2023 3:35pm
136 Views
Post# 35612610

"Finally Some Good News" On Cannabis, says Wedbush

"Finally Some Good News" On Cannabis, says Wedbush 2023-08-30 03:23:23 PM ET (MT Newswires)

03:23 PM EDT, 08/30/2023 (MT Newswires) -- Today, in what was "very encouraging news" for the sector, the U.S. Dep't of Health and Human Services (HHS) officially recommended to the U.S. Drug Enforcement Administration (DEA) that cannabis be moved from its current Schedule I to Schedule III of the Controlled Substances Act, Wedbush said Wednesday. 
 
Following its scientific review of cannabis, the HHS now believes cannabis should be moved to a lower schedule (Schedule III) within the Controlled Substances Act, given it is currently marked as a Schedule I drug. Wedbush noted while the recommendation is not binding, and the decision will ultimately depend on the DEA's ruling, the HHS' analysis will likely influence the DEA's decision.
 
Wedbush said: "While cannabis would still remain federally illegal as a Schedule III drug, rescheduling it to a lower Schedule would have significant, industry wide implications, chief among which would be the relief from punitive 280E tax provision, arguably the most penal of all regulatory hurdles facing multi-state operators (MSOs), which effectively requires operators to pay effective tax rates between 60-90%. To be sure, rescheduling cannabis from Schedule I to Schedule III would be materially beneficial from a profitability and cash flow perspective, at a time when all MSOs are focused on cash preservation."
 
In its take, Wedbush said it views today's news as "very encouraging" for an industry that has seen no meaningful regulatory progress over the past few years, and particularly since the failure of lawmakers to pass SAFE during last year's lame duck session. "While the recommendation has yet to be confirmed by the DEA, we view this as a positive development, which materially increase the odds of a rescheduling to Schedule III, which as mentioned would be a boon for the industry," it added.
<< Previous
Bullboard Posts
Next >>